Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme.

IF 4.7 3区医学 Q1 INFECTIOUS DISEASES

Infectious Diseases and Therapy Pub Date : 2025-01-01 Epub Date: 2024-11-26 DOI:10.1007/s40121-024-01073-3

Manjit Hunjan, Desmond Curran, Alen Marijam, Yasmeeta Vekria, Nikolaos Giannelos

{"title":"Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme.","authors":"Manjit Hunjan, Desmond Curran, Alen Marijam, Yasmeeta Vekria, Nikolaos Giannelos","doi":"10.1007/s40121-024-01073-3","DOIUrl":null,"url":null,"abstract":"Introduction: In 2023, recombinant zoster vaccine (RZV) replaced zoster vaccine live (ZVL) vaccine in the UK National Immunisation Programme (NIP) for prevention of herpes zoster (HZ). The vaccination age was reduced from 70 to 65 years, with a subsequent planned reduction to 60 years. This modelling study aimed to evaluate the public health impact (PHI) of RZV vaccination in the 70 years of age (YOA) population and in younger individuals 65 and 60 YOA.Methods: PHI was evaluated from a National Health Service perspective, as cases of HZ, post-herpetic neuralgia (PHN), non-PHN complications and deaths, hospitalisations, and general practitioner (GP) visits avoided using a multicohort Markov model. Three scenarios (RZV vs. no vaccination, ZVL vs. no vaccination, and RZV vs. ZVL) were explored for each age group using population estimates from the UK Office for National Statistics, i.e. 70 YOA (n = 649,822), 65 YOA (n = 760,578) and 60 YOA (n = 849,501).Results: Modelled outcomes in 70 YOA individuals estimated that RZV vaccination would avoid 32,894 cases of HZ and 5915 cases of PHN compared with no vaccination and 26,954 HZ and 3218 PHN cases compared with ZVL. Compared with no vaccination, 2264 fewer hospitalisations and 158,549 fewer GP visits were predicted with RZV vaccination. Hospitalisations were predicted to be reduced by 1996 and GP visits by 130,821 for RZV versus ZVL vaccination. In individuals 65 YOA, it was estimated that RZV vaccination would avoid 50,128 HZ cases, 8623 PHN cases, 222,646 GP visits, and 2671 hospitalisations versus no vaccination. In the 60 YOA group, RZV vaccination was predicted to avoid 57,182 HZ cases, 9327 PHN cases, 234,330 GP visits, and 2547 hospitalisations versus no vaccination.Conclusion: The recent introduction of RZV into the NIP could substantially reduce HZ disease burden and healthcare resource use in the UK. A graphical abstract is available with this article.","PeriodicalId":13592,"journal":{"name":"Infectious Diseases and Therapy","volume":" ","pages":"105-119"},"PeriodicalIF":4.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782755/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40121-024-01073-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In 2023, recombinant zoster vaccine (RZV) replaced zoster vaccine live (ZVL) vaccine in the UK National Immunisation Programme (NIP) for prevention of herpes zoster (HZ). The vaccination age was reduced from 70 to 65 years, with a subsequent planned reduction to 60 years. This modelling study aimed to evaluate the public health impact (PHI) of RZV vaccination in the 70 years of age (YOA) population and in younger individuals 65 and 60 YOA.

Methods: PHI was evaluated from a National Health Service perspective, as cases of HZ, post-herpetic neuralgia (PHN), non-PHN complications and deaths, hospitalisations, and general practitioner (GP) visits avoided using a multicohort Markov model. Three scenarios (RZV vs. no vaccination, ZVL vs. no vaccination, and RZV vs. ZVL) were explored for each age group using population estimates from the UK Office for National Statistics, i.e. 70 YOA (n = 649,822), 65 YOA (n = 760,578) and 60 YOA (n = 849,501).

Results: Modelled outcomes in 70 YOA individuals estimated that RZV vaccination would avoid 32,894 cases of HZ and 5915 cases of PHN compared with no vaccination and 26,954 HZ and 3218 PHN cases compared with ZVL. Compared with no vaccination, 2264 fewer hospitalisations and 158,549 fewer GP visits were predicted with RZV vaccination. Hospitalisations were predicted to be reduced by 1996 and GP visits by 130,821 for RZV versus ZVL vaccination. In individuals 65 YOA, it was estimated that RZV vaccination would avoid 50,128 HZ cases, 8623 PHN cases, 222,646 GP visits, and 2671 hospitalisations versus no vaccination. In the 60 YOA group, RZV vaccination was predicted to avoid 57,182 HZ cases, 9327 PHN cases, 234,330 GP visits, and 2547 hospitalisations versus no vaccination.

Conclusion: The recent introduction of RZV into the NIP could substantially reduce HZ disease burden and healthcare resource use in the UK. A graphical abstract is available with this article.

查看原文本刊更多论文

在英国国家免疫计划中引入佐剂重组带状疱疹疫苗的公共卫生影响模型。

简介：2023 年，在英国国家免疫计划 (NIP) 中，重组带状疱疹疫苗 (RZV) 取代了带状疱疹活疫苗 (ZVL)，用于预防带状疱疹 (HZ)。疫苗接种年龄从 70 岁降至 65 岁，随后计划降至 60 岁。这项模拟研究旨在评估 RZV 疫苗接种对 70 岁 (YOA) 人口以及 65 岁和 60 岁较年轻人口的公共卫生影响 (PHI)：从国民健康服务的角度评估了 PHI，即使用多队列马尔可夫模型避免的 HZ、带状疱疹后神经痛 (PHN)、非 PHN 并发症和死亡病例、住院和全科医生 (GP) 就诊。利用英国国家统计局的人口估计数，对每个年龄组的三种情况（RZV 与不接种疫苗、ZVL 与不接种疫苗、RZV 与 ZVL）进行了探讨，即 70 YOA（n = 649,822 人）、65 YOA（n = 760,578 人）和 60 YOA（n = 849,501 人）：根据对 70 YOA 个人的模拟结果估计，与不接种疫苗相比，接种 RZV 可避免 32,894 例 HZ 和 5915 例 PHN，与接种 ZVL 相比，可避免 26,954 例 HZ 和 3218 例 PHN。与不接种疫苗相比，接种 RZV 疫苗预计可减少 2264 例住院和 158549 次全科医生就诊。接种 RZV 与接种 ZVL 相比，住院病例预计将减少 1996 例，全科医生就诊次数预计将减少 130,821 次。据估计，在 65 岁以上的人群中，接种 RZV 与不接种相比，可避免 50128 例 HZ 病例、8623 例 PHN 病例、222646 次全科医生就诊和 2671 例住院。在 60 YOA 组中，接种 RZV 与不接种相比，预计可避免 57,182 例 HZ 病例、9327 例 PHN 病例、234,330 次全科医生就诊和 2547 次住院治疗：结论：最近将 RZV 引入国家免疫计划可大幅减少英国的 HZ 疾病负担和医疗资源使用。本文附有图表摘要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious Diseases and Therapy Medicine-Microbiology (medical)

CiteScore

8.60

自引率

1.90%

发文量

136

审稿时长

6 weeks

期刊介绍： Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.